High dose chemotherapy in ovarian cancer

Pujade-Lauraine, Éric; Curé, Hervé; Battista, C.; Guastalla, Jean‐Paul; Chiurazzi, Bruno; Fabbro, Michel; Tubiana-Mathieu, Nicole; Bourgeois, H.; Lioure, Bruno; Paraïso, D.; Lotz, Jean‐Pierre

doi:10.1046/j.1525-1438.2001.11(suppl.1)sup1064.x

Cited by 16 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical trials of autologous SCT in chemosensitive ovarian cancer (achieving CR after primary optimal cytoreduction and adjuvant chemotherapy) may further improve disease control; however, this approach remains to be investigated (21,22) . Clinical trials of autologous SCT in chemosensitive ovarian cancer (achieving CR after primary optimal cytoreduction and adjuvant chemotherapy) may further improve disease control; however, this approach remains to be investigated (21,22) .…”

Section: Discussionmentioning

confidence: 99%

Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer

See

Thomas

Bueso-Ramos

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

Abstract. See HT, Thomas DA, Bueso‐Ramos C, Kavanagh J. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl. 1):236–240. The occurrence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported after treatment with cytotoxic alkylating agent–based chemotherapy for solid tumors. We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia. The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade. Monitoring of the long‐term outcome of paclitaxel‐ and platinum‐based regimens is warranted, particularly with regard to monitoring the development of secondary MDS and/or AML. The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer

See

Thomas

Bueso-Ramos

et al. 2006

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Subsequent trials with one or multiple cycles of HDCT have found similar results. 13,14,[26][27][28][29] Because HDCT does not appear effective in advanced High-dose therapy for advanced ovarian cancer C Papadimitriou et al refractory patients, investigators focused their attention on patients with earlier, less resistant and less bulky disease. In this context, HDCT has been given either after debulking surgery and standard conventional-dose platinum containing chemotherapy or as a part of the initial treatment plan.…”

Section: Discussionmentioning

confidence: 99%

High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial

Papadimitriou

Dafni

Anagnostopoulos

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Et la purge des cellules souches hé matopoïé tiques n'a jamais é té validé e. Dans le cancer de l'ovaire, l'analyse des donné es de la chimiothé rapie intensive de rattrapage permet d'affirmer que cette procé dure permet d'obtenir un taux é levé de ré ponses, voisin de 70 dont 30 % de ré ponse complè te, alors que la probabilité de ré ponse à une chimiothé rapie de deuxiè me ligne n'excè de pas les 30 %. Cependant, la morbidité pré coce est forte (environ 20 %) dans cette population pré traité e et la duré e de ré ponse est courte, de l'ordre de 3 à 8,5 mois [20]. C'est pourquoi la chimiothé rapie intensive dans le cancer é volué de l'ovaire ne s'est dé veloppé e qu'en situation de consolidation.…”

Section: Les Approches Thé Rapeutiquesunclassified